Latest News

Tonix’s stock jumps 43% on patent for experimental pox vaccines


Shares of Tonix Pharmaceuticals Holding Corp.

gained 43.8% in premarket trading on Wednesday after the company said the U.S. Patent and Trademark Office issued a patent to the company’s poxvirus vaccine and its recombinant poxvirus platform. The horsepox-based live virus vaccine is being developed against monkeypox and smallpox. The patent gives the company market exclusivity until 2037. Tonix’s stock has tumbled 78.7% so far this year, while the S&P 500

is down 13.3%.

I’ve found that a financial adviser can easily cost $5,000 a year. Is paying an adviser really worth this kind of money?

Previous article

Stock market news live updates: Stocks slide after data impresses, Dimon warns

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News